Table 2

Key economic outputs (base case and sensitivity analyses)

ArmCosts*QALYsICER (£/QALY gained)
Base case†
 TAVI£30 200 (£27 829, £32 833)2.36 (2.19, 2.43)
 MM£5000 (£3995, £6005)0.80 (0.61, 1.02)
 Difference+£25 200+1.5616 200
ArmCosts*QALYsICER (£/QALY gained)
Analysis 1: Pooled parameter values and PARTNER-B survival data†
TAVI£30 600 (£27 758, £32 946)2.34 (2.19, 2.43)
MM£5000 (£4042, £6101)0.80 (0.62, 1.02)
Difference+£25 600+1.54£16 600
Source24 month survivalDerived multiplier‡ICER (£/QALY gained)
Analysis 2: Impact of using alternative data sources for medical management mortality
Leon et al1450.3%NA
Dewey et al881.0%0.63£14 300
Bouma et al2544.1%1.14£18 500
Varadarajan et al2656.7%0.89£16 100
SourceBaseline decrementICER (£/QALY gained)
Immediate benefitTime-dependent benefit
Analysis 3: Impact of using alternative sources and assumptions for TAVI-related utility
SF-6D0.107§£17 700£18 400
EQ-5D0.153£16 900£17 600
NYHA III0.187**£16 400£17 000
NYHA IV0.357††£19 500£14 500
PARTNER0.201‡‡£17 500£16 700

  • ↵* Rounded to nearest £100.

  • ↵† Probabilistic rather than deterministic outputs. Information corresponds to mean and 95% credibility intervals.

  • ↵‡ Represents the ratio of study specific and PARTNER 24-month survival estimates. Applied to the baseline probabilities in both treatment and comparator arm.

  • ↵§ Derived from information in Bach et al27 using mapping algorithm presented in Ara et al.28

  • ↵ Based on information in COR 2006-02 study: Medtronic data on file.

  • ↵** Severe aortic stenosis assumed to be same as NYHA III. Value taken from Fox et al.20

  • ↵†† Severe aortic stenosis assumed to be same as NYHA IV. Value taken from Fox et al.20

  • ↵‡‡ Published values used in combination with baseline NYHA mix to generate average decrement.

  • GW, general ward; ICER, incremental cost-effectiveness ratio; MM, medical management; NYHA, New York Heart Association; QALY, quality-adjusted life year; TAVI, transcatheter aortic valve implantation.